CN1803155A - Medicine for curing rhinitis - Google Patents
Medicine for curing rhinitis Download PDFInfo
- Publication number
- CN1803155A CN1803155A CNA2005100201675A CN200510020167A CN1803155A CN 1803155 A CN1803155 A CN 1803155A CN A2005100201675 A CNA2005100201675 A CN A2005100201675A CN 200510020167 A CN200510020167 A CN 200510020167A CN 1803155 A CN1803155 A CN 1803155A
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- polyethylene glycol
- sus domestica
- fructus xanthii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicament for treating rhinitis, which comprises Xanthium sibiricum extract 2.0-3.5 parts, patchouli oil 0.5-1.5 parts, dried pig bladder powder 2.0-3.0 part, and polyethylene glycol 7.5-30 parts. the invention also discloses the process for preparing the medicament.
Description
Technical field
The present invention relates to the pharmaceutical technology field, relate to a kind of medicine for the treatment of rhinitis or rather.
Background technology
Rhinitis is meant that inflammation appears in nasal membrane; show as hyperemia or edema; the patient nasal obstruction occurs through regular meeting, stream clear water tears, rhinocnesmus; throat's discomfort; symptoms such as cough, Epidemiological study show that its prevalence is greatly about about 15%; have a strong impact on people's life, working and learning, the headache that is brought, nasal obstruction, sneeze are having a strong impact on patient's quality of life.Rhinitis is the most common with chronic rhinitis and allergic rhinitis.
The western medicine of rhinitis mainly is the symptomatic treatment at nasal obstruction, as select 1% ephedrine nasal drop for use, also do not have obviously and alleviate but part rhinitis patient is dripped behind the ephedrine nasal obstruction, and can cause olfactory disorder, headache, hypomnesis, and might cause " medicamentous rhinitis "; Also select for use antihistaminic class medicine such as chlorphenamine oral, but the side effect that it has cental system to suppress; The steroid hormone oral formulations also is usually used in the treatment of allergic rhinitis, can produce water, salt, sugar, protein metabolism disorder but use always; Rhinitis also can adopt method treatments such as freezing, laser, sealing, sclerosing agent, operation than severe patient, implement but all need arrive medical institutions with good conditionsi, and it is inconvenient to use, and the expense costliness.
The course of disease of chronic rhinitis and allergic rhinitis is longer, generally needs long-term prescription, can avoid the side effect of Western medicine with treatment by Chinese herbs, and reaches the effect for the treatment of both the principal and secondary aspects of a disease.The Chinese patent medicine of treatment rhinitis mainly contains QIANBAI BIYAN PIAN, XINQIN granule etc. at present, but still can not satisfy patient's medication needs, because of directly being used as medicine of having with the crude drug powder without extracting, problem such as be difficult to solve the existence of medical material self antibacterial, microorganism and grow, thereby make the effect duration of medicine short, not easy to store; Adjuvant that has such as starch or cane sugar content height, active constituent content is lower, so dose big, take inconvenience.
Summary of the invention
Purpose of the present invention just provides a kind of medicine for the treatment of rhinitis, and this medicine is used for the treatment of chronic rhinitis and allergic rhinitis determined curative effect, drug safety, little, the taking convenience of dose, and with low cost.
The technical solution adopted for the present invention to solve the technical problems is: a kind of medicine for the treatment of rhinitis, and it contains 2.0-3.5 part Fructus Xanthii extract, 0.5-1.5 part patchouli oil, 2.0-3.0 part Fel Sus domestica dry paste and 7.5-30 part Polyethylene Glycol; And the mean molecule quantity of Polyethylene Glycol is more than 400.
In the medicine of above-mentioned treatment rhinitis, the weight proportion of each component is preferably: 2.5-3.0 part Fructus Xanthii extract, 0.75-1.25 part patchouli oil, 2.2-2.6 part Fel Sus domestica dry paste, 8.5-28 part Polyethylene Glycol.More preferably: 2.85 parts of Fructus Xanthii extracts, 1 portion of patchouli oil, 2.43 parts of Fel Sus domestica dry pastes, 9.5-25 part Polyethylene Glycol.Wherein, preferred any one or a few in Polyethylene Glycol 400, Macrogol 600, Macrogol 4000, polyethylene glycol 6000 etc. of Polyethylene Glycol.
Needs according to different preparations, can also contain the other medicines composition in the medicine of above-mentioned treatment rhinitis or/and pharmaceutic adjuvant, and the other medicines composition is for being used for the treatment of Chinese medicine extract or active constituents of medicine such as Flos Magnoliae extract, the baicalin etc. of rhinitis with above-mentioned each compatibility of drugs; Pharmaceutic adjuvant is any one or a few in starch, dextrin, glycerol, vegetable oil, tween, gelatin and Cera Flava etc. preferably.
Dosage form preferred tablet, hard capsule, soft capsule, drop pill or the granule of the medicine of above-mentioned treatment rhinitis.Further preferred drop pill, and the component of this drop pill is preferably: 2.5-3.0 part Fructus Xanthii extract, 0.75-1.25 part patchouli oil, 2.2-2.6 part Fel Sus domestica dry paste, 8.5-28 part Macrogol 4000 or polyethylene glycol 6000; More preferably: 2.85 parts of Fructus Xanthii extracts, 1 portion of patchouli oil, 2.43 parts of Fel Sus domestica dry pastes, 9.5-25 part Macrogol 4000 or polyethylene glycol 6000s.
The Fructus Xanthii extract of mentioning in the medicine of the present invention, patchouli oil and Fel Sus domestica dry paste can be bought from market, and also can distinguishing by the following method, oneself prepares:
(1) preparation of Fructus Xanthii extract: get the Fructus Xanthii medical material, add the ethanol that 5-10 doubly measures, reflux, extract, three times, 2 hours for the first time, for the second time, each 1 hour for the third time, filter, merging filtrate, filtrate recycling ethanol be not to there being the alcohol flavor, extractum; The water washing secondary that in extractum, adds about 10 times of amounts, discard water layer after, precipitation is dried to dry extract, promptly make Fructus Xanthii extract.
(2) preparation of patchouli oil: get the Herba Pogostemonis medical material, extract, collect volatile oil, promptly make patchouli oil with steam distillation.
(3) preparation of Fel Sus domestica dry paste: get Fel Sus domestica, the peeling extracting juice filters, and filtrate is condensed into dried cream, and the reuse alcohol heating reflux extracts, and filters, and reclaims ethanol, concentrates, and drying promptly makes Fel Sus domestica dry paste.This product is pressed dry product and is calculated, and contains total free cholic acid and must not be less than 55.0%.
More than each component also can be by the preparation of other conventional method.
The preparation of medicine of the present invention: can be prepared from by the common process of different dosage form medicine, get final product.
Compared with prior art, the invention has the beneficial effects as follows: the raw materials used medicine wide material sources of (1) this medicine are easy to get, and are cheap, and preparation method is simple, so cost is lower.(2) contain Polyethylene Glycol in the medicine of the present invention, can obviously improve bioavailability of medicament, thereby the curative effect of medicine of the present invention is significantly improved.(3) choice of drug extract of the present invention is a raw material, have and feed intake accurately, the active constituent content height, quality controllable, dose is little, the characteristics of taking convenience, and problem such as do not have material medicine directly to pulverize to be used as medicine the existence of the antibacterial that causes, microorganism and grow, thus the effect duration of medicine grow, easy to store.(4) compare with chemicals, poisonous side effect of medicine of the present invention is less, and safety is good.
For confirming medicine excellent curative of the present invention and safety, the inventor has carried out pharmacodynamics and acute toxicity test is investigated.The research method and the result of the test that are adopted are as follows:
(1) test material
Medicine and reagent: medicine low dose group of the present invention (dosage: 0.3g/kg), (dosage: 0.6g/kg), medicine high dose group (dosage: 1.2g/kg) of the present invention of dosage group in the medicine of the present invention.The drugs compared (0.3g/kg) that does not contain Polyethylene Glycol.Dexamethasone acetate tablets, Tianjin pharmaceutcal corporation, Ltd produces.Dimethylbenzene, chemical reagent factory in Chengdu produces.Radix Tripterygii Wilfordii tablet, Huangshi pharmaceutical factory produces.
The weight proportion of each component is in the medicine of the present invention: 2.85 parts of Fructus Xanthii extracts, 1 portion of patchouli oil, 2.43 parts of Fel Sus domestica dry pastes, 10 parts of Macrogol 4000s.
The weight proportion that does not contain each component in the drugs compared of Polyethylene Glycol is: 2.85 parts of Fructus Xanthii extracts, 1 portion of patchouli oil, 2.43 parts of Fel Sus domestica dry pastes.
Animal: Kunming mouse, the SD rat is provided by institute of antibiotics, Sichuan Experimental Animal Center.
(2) test method and result
1. the influence of xylol induced mice ear swelling
Choose 60 Kunming mouses, male, body weight 18～22g is divided into 6 groups at random by body weight, 10 every group.Press the listed dosage of table 1, gastric infusion, matched group is irritated stomach isometric(al) distilled water, for three days on end, and every day 1 time, 60min after the last administration, each treated animal is applied to auricle two sides, a mice left side with dimethylbenzene 50 μ l and causes inflammation, cuts ears after causing scorching 30min, and hammer is got ears same area auricle, weigh, be calculated as follows swelling degree and inhibitory rate of intumesce.The results are shown in Table 1.
Swelling degree=cause inflammation is picked up the ears, and to cause the inflammation sheet of picking up the ears heavy for sheet weight-non-
The influence of table 1 xylol induced mice ear swelling (x ± SD)
| Group | Dosage * number of times (g/kg * c) | Mus number (only) | Swelling degree (mg) | Inhibitory rate of intumesce (%) |
| Dosage medicine group of the present invention low dosage does not contain the drugs compared dexamethasone tablet group of polyethylene glycol in the control group medicine group of the present invention high dose medicine group of the present invention | Equal-volume distilled water * 3 1.2 * 3 0.6 * 3 0.3 * 3 0.3 * 3 0.03 * 3 | 10 10 10 10 10 10 | 10.5±2.1 6.9±1.8 ** 7.5±2.3 ** 7.9±2.5 * 8.3±2.1 6.7±2.5 ** | - 34.28 28.57 24.76 20.95 36.19 |
Annotate: each administration group and matched group are relatively
*P＜0.05;
*P＜0.01;
* *P＜0.001.
Table 1 shows that medicine xylol induced mice ear swelling of the present invention has remarkable inhibitory action (* * P＜0.01), illustrates that medicine of the present invention has significant antiinflammatory action.
2. to the influence of capillary of skin permeability
72 of rats, male and female half and half, divide 6 groups at random, every group 12,, press the listed dosage of table 2 in the both sides depilation of preceding 24 hours spines of test, behind gastric infusion or normal saline (matched group) 2h, inject the normal saline solution 0.1ml of histamine (including the 80 μ g of histamine) at every back part of animal both sides depilation place Intradermal, the 0.5% azovan blue solution 0.5ml of intravenous injection simultaneously, the size of the subcutaneous locus coeruleus area of mensuration after 30 minutes.The results are shown in Table 2.
The influence of table 2 pair capillary of skin permeability (x ± SD)
| Group | Dosage (g/kg) | Mus number (only) | Locus coeruleus area (cm 2) |
| Dosage medicine group of the present invention low dosage does not contain the drugs compared dexamethasone tablet group of polyethylene glycol in the control group medicine group of the present invention high dose medicine group of the present invention | Equal-volume distilled water 1.2 0.6 0.3 0.3 0.03 | 12 12 12 12 12 12 | 2.54±1.21 1.44±0.77 *** 1.76±1.12 ** 1.88±1.35 ** 1.91±1.47 ** 0.71±0.21 *** |
Annotate: each administration group and model group are relatively
*P＜0.05;
*P＜0.01;
* *P＜0.001.
Table 2 shows, medicine of the present invention can obviously suppress the increase of the capillary of skin permeability that histamine causes, can alleviate the swelling that is produced by inflammation, alleviates nasal obstruction.
3. to the influence of mice passive cutaneous anaphylaxis, PCA
Get 10 of male mices, about 20 grams of body weight inject two soles of 0.05ml. 0.1ml altogether with Radix Trichosanthis gel aluminum hydroxide suspension (face time spent be dissolved among the 5% gel aluminum hydroxide 1ml with the 2.5mg Radix Trichosanthis) in two hind paws of every mice; After 15 days, broken end is got blood, and the centrifuging and taking antiserum is standby.Other gets 60 of male mices, and body weight 20 ± 1g divides 6 groups at random, 10 every group, respectively organizes listed dosage by table 3, continuous 4 days of of every day gastric infusion or distilled water (matched group).Get above-mentioned antiserum and add normal saline and be diluted to 1: 5, each Mus stomach wall intradermal injection 2 point (at a distance of 0.2cm), every some 0.03ml.And successive administration 2 days, after 12 hours, 0.2ml/ is only for the Radix Trichosanthis of every mouse mainline 2.5mg/ml (with the preparation of 1% azovan blue, one physiology saline) in the last administration, sacrificed by decapitation animal after 20 minutes, the upset skin of abdomen, the diameter of mensuration locus coeruleus the results are shown in Table 3.
The influence of table 3 pair mice passive anaphylaxis (x ± SD)
| Group | Dosage (g/kg) | Mus number (only) | Locus coeruleus diameter (cm) |
| Dosage medicine group of the present invention low dosage does not contain the drugs compared leigongteng tablets group of polyethylene glycol in the control group medicine group of the present invention high dose medicine group of the present invention | Equal-volume distilled water 1.2 0.6 0.3 0.3 0.02 | 10 10 10 10 10 10 | 1.28±0.24 0.41±0.31 *** 0.51±0.29 ** 0.67±0.26 ** 0.84±0.35 * 0.30±0.12 *** |
Annotate: each administration group and matched group are relatively
*P＜0.05;
*P＜0.01;
* *P＜0.001.
Table 3 shows that medicine of the present invention has obvious inhibitory action to the mice passive cutaneous anaphylaxis, PCA, confirms medicine tool anti-allergic effects of the present invention, can be used for allergic rhinitis.
4. acute toxicity test
The inventor has carried out the acute toxicity test investigation with mice to medicine of the present invention, and the result is: when the maximum dosage-feeding of medicine mouse stomach of the present invention administration is 62g/kg/24h, do not have a mice overt toxicity reaction symptom to occur; This dosage is about 1107 times of 60kg body weight adult's clinical oral administration day dosage (0.056g/kg).The result shows that safety of medicine dosage range of the present invention is bigger.
The specific embodiment
The present invention is described in further detail below in conjunction with the specific embodiment.
Embodiment one
Medicine of the present invention is a drop pill, and its component is: 2.85 parts of Fructus Xanthii extracts, 1 portion of patchouli oil, 2.43 parts of Fel Sus domestica dry pastes and 15 parts of Macrogol 4000s.
Make the drop pill of certain specification by the common process of preparation drop pill.
Embodiment two
Medicine of the present invention is a drop pill, and its component is: 2.5 parts of Fructus Xanthii extracts, 1.25 portions of patchouli oils, 2.6 parts of Fel Sus domestica dry pastes and 25 parts of polyethylene glycol 6000s.
Make the drop pill of certain specification by the common process of preparation drop pill.
Embodiment three
Medicine of the present invention is a drop pill, and its component is: 3 parts of Fructus Xanthii extracts, 0.75 portion of patchouli oil, 2.2 parts of Fel Sus domestica dry pastes and 9.5 parts of Macrogol 4000s.
Make the drop pill of certain specification by the common process of preparation drop pill.
Embodiment four
Medicine of the present invention is a drop pill, and its component is: 2 parts of Fructus Xanthii extracts, 1.5 portions of patchouli oils, 3 parts of Fel Sus domestica dry pastes and 8.5 parts of Polyethylene Glycol 2500.
Make the drop pill of certain specification by the common process of preparation drop pill.
Embodiment five
Medicine of the present invention is a drop pill, and its component is: 3.5 parts of Fructus Xanthii extracts, 0.5 portion of patchouli oil, 2 parts of Fel Sus domestica dry pastes, 25 parts of Macrogol 4000s and 3 parts of Polyethylene Glycol 2500.
Make the drop pill of certain specification by the common process of preparation drop pill.
Embodiment six
Medicine of the present invention is a drop pill, and its component is: 2.25 parts of Fructus Xanthii extracts, 0.8 portion of patchouli oil, 2.8 parts of Fel Sus domestica dry pastes, 20 parts of Macrogol 4000s and 10 parts of polyethylene glycol 6000s.
Make the drop pill of certain specification by the common process of preparation drop pill.
Embodiment seven
Medicine of the present invention is a soft capsule, and the component of its content is: 2.85 parts of Fructus Xanthii extracts, 1 portion of patchouli oil, 2.43 parts of Fel Sus domestica dry pastes, 7 parts of vegetable oil and 15 parts of PEG400s; Soft capsule shell component and method routinely made.
Make the soft capsule of certain specification by the common process of preparation soft capsule.
Embodiment eight
Medicine of the present invention is a soft capsule, and the component of its content is: 2.5 parts of Fructus Xanthii extracts, 1.25 portions of patchouli oils, 2 parts of Fel Sus domestica dry pastes, 6 parts of vegetable oil, 0.03 part of Tween 80 and 7.5 parts of Macrogol 600s; Soft capsule shell component and method routinely made.
Make the soft capsule of certain specification by the common process of preparation soft capsule.
Embodiment nine
Medicine of the present invention is a soft capsule, and the component of its content is: 2 parts of Fructus Xanthii extracts, 1.5 portions of patchouli oils, 2.6 parts of Fel Sus domestica dry pastes, 8 parts of vegetable oil and 10 parts of PEG400s; Soft capsule shell component and method routinely made.
Make the soft capsule of certain specification by the common process of preparation soft capsule.
Embodiment ten
Medicine of the present invention is a soft capsule, and the component of its content is: 3 parts of Fructus Xanthii extracts, 0.5 portion of patchouli oil, 2.2 parts of Fel Sus domestica dry pastes, 9 parts of vegetable oil, 8 parts of Polyethylene Glycol 800 and 2 parts of Cera Flavas; Soft capsule shell component and method routinely made.
Make the soft capsule of certain specification by the common process of preparation soft capsule.
Embodiment 11
Medicine of the present invention is a tablet, and its component is: 3.5 parts of Fructus Xanthii extracts, 0.75 portion of patchouli oil, 3 parts of Fel Sus domestica dry pastes, 7.5 parts of Polyethylene Glycol 2500 and 5 parts of dextrin.
Make the tablet of certain specification by the common process of preparation tablet.
Embodiment 12
Medicine of the present invention is a hard capsule, and its component is: 2.75 parts of Fructus Xanthii extracts, 1 portion of patchouli oil, 2.25 parts of Fel Sus domestica dry pastes, 12 parts of polyethylene glycol 6000s and 15 parts of starch.
Make the hard capsule of certain specification by the common process of preparation hard capsule.
Embodiment 13
Medicine of the present invention is a granule, and its component is: 2.9 parts of Fructus Xanthii extracts, 1 portion of patchouli oil, 2.2 parts of Fel Sus domestica dry pastes, 18 parts of Macrogol 4000s, 12 portions of sucrose.
Make the granule of certain specification by the common process of preparation granule.
Claims (8)
1, a kind of medicine for the treatment of rhinitis, it contains 2.0-3.5 part Fructus Xanthii extract, 0.5-1.5 part patchouli oil, 2.0-3.0 part Fel Sus domestica dry paste and 7.5-30 part Polyethylene Glycol; And the mean molecule quantity of Polyethylene Glycol is more than 400.
2, the medicine of treatment rhinitis according to claim 1 is characterized in that: the weight proportion of described each component is: 2.5-3.0 part Fructus Xanthii extract, 0.75-1.25 part patchouli oil, 2.2-2.6 part Fel Sus domestica dry paste, 8.5-28 part Polyethylene Glycol.
3, the medicine of treatment rhinitis according to claim 2 is characterized in that: the weight proportion of described each component is: 2.85 parts of Fructus Xanthii extracts, 1 portion of patchouli oil, 2.43 parts of Fel Sus domestica dry pastes, 9.5-25 part Polyethylene Glycol.
4, the medicine of treatment rhinitis according to claim 1 is characterized in that: described Polyethylene Glycol is to be selected from PEG400, Macrogol 600, Macrogol 4000, the polyethylene glycol 6000 any one or a few.
5, the medicine of treatment rhinitis according to claim 1, it is characterized in that: also contain the other medicines composition in this medicine or/and pharmaceutic adjuvant, and pharmaceutic adjuvant is to be selected from starch, dextrin, glycerol, vegetable oil, tween, gelatin and the Cera Flava any one or a few.
6, the medicine of treatment rhinitis according to claim 1 is characterized in that: the dosage form of this medicine is tablet, hard capsule, soft capsule, drop pill or granule.
7, the medicine of treatment rhinitis according to claim 6, it is characterized in that: the dosage form of this medicine is a drop pill, and its component is: 2.5-3.0 part Fructus Xanthii extract, 0.75-1.25 part patchouli oil, 2.2-2.6 part Fel Sus domestica dry paste, 8.5-28 part Macrogol 4000 or polyethylene glycol 6000.
8, the medicine of treatment rhinitis according to claim 7 is characterized in that: the component of described drop pill is: 2.85 parts of Fructus Xanthii extracts, 1 portion of patchouli oil, 2.43 parts of Fel Sus domestica dry pastes, 9.5-25 part Macrogol 4000 or polyethylene glycol 6000s.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100201675A CN1803155A (en) | 2005-01-14 | 2005-01-14 | Medicine for curing rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100201675A CN1803155A (en) | 2005-01-14 | 2005-01-14 | Medicine for curing rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1803155A true CN1803155A (en) | 2006-07-19 |
Family
ID=36865388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005100201675A Pending CN1803155A (en) | 2005-01-14 | 2005-01-14 | Medicine for curing rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1803155A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101439083B (en) * | 2007-11-19 | 2011-08-17 | 北京亚东生物制药有限公司 | Detection method of Chinese medicine soft capsules for clearing wind heat and clearing nasal passage |
| CN103417640A (en) * | 2013-01-29 | 2013-12-04 | 李琼 | Medicine for treating acute and chronic rhinitis and nasosinusitis |
| CN113018504A (en) * | 2021-03-11 | 2021-06-25 | 华沃生物科技(武汉)有限公司 | Anti-allergic nasal liquid dressing and preparation method thereof |
-
2005
- 2005-01-14 CN CNA2005100201675A patent/CN1803155A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101439083B (en) * | 2007-11-19 | 2011-08-17 | 北京亚东生物制药有限公司 | Detection method of Chinese medicine soft capsules for clearing wind heat and clearing nasal passage |
| CN103417640A (en) * | 2013-01-29 | 2013-12-04 | 李琼 | Medicine for treating acute and chronic rhinitis and nasosinusitis |
| CN113018504A (en) * | 2021-03-11 | 2021-06-25 | 华沃生物科技(武汉)有限公司 | Anti-allergic nasal liquid dressing and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1943689A (en) | A Chinese traditional medicinal composition for treatment of wind-heat type common cold and its preparation method | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN1210047C (en) | Medicine for treating cold and preparation method thereof | |
| CN1803155A (en) | Medicine for curing rhinitis | |
| CN1397560A (en) | Process for extracting general platycodoside and platycoligenin D from platycodon root, its medical application and its Chinese medicine | |
| CN1631902A (en) | Angelica polysaccharide and its preparation and use | |
| CN1453295A (en) | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition | |
| CN1943632A (en) | A kind of medicine for treating infant cold and its preparing method | |
| CN1244332C (en) | Sarcandra extract and its application | |
| CN1857492A (en) | Qingxie preparation and its preparing process | |
| CN1236810C (en) | Gastritis treating Chinese medicine | |
| CN1927289A (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and its preparation | |
| CN1742926A (en) | Zuoci preparation for deaf and new preparing method thereof | |
| CN1166389C (en) | Inhalation 'Shangfengjing' and its preparing process | |
| CN1203891C (en) | Medicine for treating coronary heart disease and its preparation method | |
| CN1895458A (en) | Compound Chinese-medicinal extract for treating gynaopathy and its preparation | |
| CN1267095C (en) | Application use of dihydromyricetrin | |
| CN1850188A (en) | Bonus fluid extract and preparing method therefor | |
| CN1259938C (en) | Chinese medicine compound preparation for treating cough and its preparing method | |
| CN1682986A (en) | Chinese medicine composition for treating urogenital system disease and its preparing method and use | |
| CN1256942C (en) | Application of dihydromyricetrin | |
| CN1308017C (en) | Medicine composition for treating eliminateion, dysentery and eruptive disease | |
| CN1429834A (en) | Fructus gleditsiae total saponin, its preparation method and use in preparation of medicine | |
| CN1850189A (en) | Bonus syrup and its preparing technology | |
| CN1846715A (en) | Chinese pearleaf crabapple oral liquid and its prepn process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |